Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch

AYTU BIOPHARMA, INC

Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.
Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.
Follows earlier $16.6M public offering closed earlier in June 2025.

item 1.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.